Dr Reddys Company Insiders

RDY Stock  USD 74.57  0.55  0.74%   
Dr Reddys employs about 25.9 K people. The company is managed by 56 executives with a total tenure of roughly 416 years, averaging almost 7.0 years of service per executive, having 461.84 employees per reported executive. Break down of Dr Reddys' management performance can provide insight into the company performance.
M Ramana  CEO
Chief Executive Officer, Branded Markets (India and Emerging Markets)
Satish Reddy  Chairman
Co-Chairman of the Board
  
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Dr Reddys Laboratories. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in unemployment.

Dr Reddys' Workforce Through the Years

Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Dr Reddys' future performance. Based on our forecasts, it is anticipated that RDY will maintain a workforce of slightly above 25860 employees by May 2024.
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid

Dr Reddys Management Team Effectiveness

The company has Return on Asset of 0.1238 % which means that on every $100 spent on assets, it made $0.1238 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.2139 %, implying that it generated $0.2139 on every 100 dollars invested. Dr Reddys' management efficiency ratios could be used to measure how well Dr Reddys manages its routine affairs as well as how well it operates its assets and liabilities. Return On Capital Employed is likely to rise to 0.38 in 2024, whereas Return On Tangible Assets are likely to drop 0.11 in 2024. At this time, Dr Reddys' Other Assets are fairly stable compared to the past year. Non Currrent Assets Other is likely to rise to about 15.4 B in 2024, whereas Total Assets are likely to drop slightly above 206.1 B in 2024.
Net Income Applicable To Common Shares is likely to rise to about 54.4 B in 2024, whereas Common Stock Shares Outstanding is likely to drop slightly above 175.2 M in 2024.

Dr Reddys Workforce Comparison

Dr Reddys Laboratories is currently regarded as top stock in number of employees category among related companies. The total workforce of Health Care industry is at this time estimated at about 26,515. Dr Reddys totals roughly 25,863 in number of employees claiming about 98% of equities under Health Care industry.

Dr Reddys Profit Margins

The company has Net Profit Margin of 0.19 %, which implies that it may need a different competitive strategy as even a very small decline in it revenue may erase profits and result in a net loss. This is way below average. In the same way, it shows Net Operating Margin of 0.25 %, which entails that for every 100 dollars of revenue, it generated $0.25 of operating income.
Current ValueLast YearChange From Last Year 10 Year Trend
Gross Profit Margin0.440.74
Way Down
Slightly volatile
Net Profit Margin0.120.21
Way Down
Pretty Stable
Operating Profit Margin0.370.35
Notably Up
Slightly volatile
Pretax Profit Margin0.110.22
Way Down
Very volatile
Return On Assets0.08830.16
Way Down
Slightly volatile
Return On Equity0.140.22
Way Down
Very volatile

Dr Reddys Laboratories Benchmark Summation

Operator
The output start index for this execution was zero with a total number of output elements of sixty-one. Dr Reddys Laboratories Price Series Summation is a cross summation of Dr Reddys price series and its benchmark/peer.

Dr Reddys Notable Stakeholders

A Dr Reddys stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Dr Reddys often face trade-offs trying to please all of them. Dr Reddys' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Dr Reddys' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
MARC KIKUCHIChief Executive Officer, North America GenericsProfile
Venkata MBACEO CouncilProfile
Patrick AghanianChief Executive Officer, European GenericsProfile
M RamanaChief Executive Officer, Branded Markets (India and Emerging Markets)Profile
Satish ReddyCo-Chairman of the BoardProfile
G PrasadCo-Chairman of the Board, Chief Executive Officer, Managing DirectorProfile
Samiran DasExecutive Vice President Head - FTO and GGPMProfile
Amit BiswasExecutive Vice President - Integrated Product DevelopmentProfile
K RaoSr. Vice President & Head – Chemical Technical Operations (CTO)Profile
Raghav ChariSenior Vice President - Proprietary ProductsProfile
Umang VohraExecutive Vice President Head - North America GenericsProfile
Cartikeya ReddySenior Vice President Head - BiologicsProfile
Alok SonigSenior Vice President & India Business Head (Generics)Profile
J RamachandranExecutive Vice President-Management Systems and Corporate InitiativesProfile
Saumen ChakrabortyPresident, Chief Financial Officer and Global Head of ITBPE, Legal and Compliance and FMCREProfile
Ganadhish KamatExecutive Vice President and Global Head-QualityProfile
Sripada ChandrasekharPresident, Global Head of HR and Member of Management CouncilProfile
Parag AgarwalChief Financial Officer - DesignateProfile
Abhijit MukherjeeCOOProfile
Erez IsraeliChief Operating Officer and Global Head of Generics & PSAIProfile
Leo PuriNon-Executive Independent DirectorProfile
Ravi BhoothalingamNon-Executive Independent DirectorProfile
Prasad MenonLead Non-Executive Independent DirectorProfile
Shikha SharmaNon-Executive Independent DirectorProfile
Omkar GoswamiNon-Executive Independent DirectorProfile
Bharat DoshiNon-Executive Independent DirectorProfile
Bruce CarterNon-Executive Independent DirectorProfile
Hans HaslerAdditional Independent DirectorProfile
Allan ObermanNon-Executive Independent DirectorProfile
Sridar IyengarNon-Executive Independent DirectorProfile
Kalpana MorpariaNon-Executive Independent DirectorProfile
J MoreauNon-Executive Independent DirectorProfile
Ashok GangulyNon-Executive Independent DirectorProfile
Anupam PuriNon-Executive Independent DirectorProfile
Sandeep PoddarCompliance Officer, Company SecretaryProfile
Kedar UpadhyeIR Contact OfficerProfile
Sanjay BTechGlobal VPProfile
K KrishnanAdditional Independent DirectorProfile
Gunupati BEMD CoChairmanProfile
Raymond VreGlobal Head of BiologicsProfile
Archana BhaskarChief Human Resource OfficerProfile
Erez MBACEO CouncilProfile
MS BTechChairman CouncilProfile
Deepak SapraGlobal Head of Pharmaceutical Services and Active IngredientsProfile
Penny WanAdditional Independent DirectorProfile
P YugandharGlobal Head of Supply ChainProfile
Sauri GudlavalletiGlobal Head of Integrated Product Development OrganizationProfile
YUGANDHAR PUVVALAGlobal Head of Supply ChainProfile
K SinghChief Compliance Officer, Company SecretaryProfile
Anil NamboodiripadGlobal Head of Proprietary ProductsProfile
SANJAY SHARMAGlobal Head of ManufacturingProfile
Vivek MittalInterim Compliance Officer, General CounselProfile
Saunak SavlaIR Contact OfficerProfile
Deepak MBACEO CouncilProfile
MBA MBACEO CouncilProfile
Mukesh RathiChief Digital and Information OfficerProfile

About Dr Reddys Management Performance

The success or failure of an entity such as Dr Reddys Laboratories often depends on how effective the management is. Dr Reddys management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of RDY management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the RDY management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last ReportedProjected for Next Year
Return On Tangible Assets 0.18  0.11 
Return On Capital Employed 0.37  0.38 
Return On Assets 0.16  0.09 
Return On Equity 0.22  0.14 
The data published in Dr Reddys' official financial statements usually reflect Dr Reddys' business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Dr Reddys Laboratories. For example, before you start analyzing numbers published by RDY accountants, it's critical to develop an understanding of what Dr Reddys' liquidity, profitability, and earnings quality are in the context of the Pharmaceuticals space in which it operates.
Please note, the presentation of Dr Reddys' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Dr Reddys' management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Dr Reddys' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Dr Reddys Laboratories. Please utilize our Beneish M Score to check the likelihood of Dr Reddys' management manipulating its earnings.

Dr Reddys Workforce Analysis

Traditionally, organizations such as Dr Reddys use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Dr Reddys within its industry.

Dr Reddys Manpower Efficiency

Return on Dr Reddys Manpower

Revenue Per Employee9.5M
Revenue Per Executive4.4B
Net Income Per Employee2.3M
Net Income Per Executive1.1B
Working Capital Per Employee4.6M
Working Capital Per Executive2.1B
When determining whether Dr Reddys Laboratories offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Dr Reddys' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Dr Reddys Laboratories Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Dr Reddys Laboratories Stock:
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Dr Reddys Laboratories. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in unemployment.
Note that the Dr Reddys Laboratories information on this page should be used as a complementary analysis to other Dr Reddys' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.

Complementary Tools for RDY Stock analysis

When running Dr Reddys' price analysis, check to measure Dr Reddys' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Dr Reddys is operating at the current time. Most of Dr Reddys' value examination focuses on studying past and present price action to predict the probability of Dr Reddys' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Dr Reddys' price. Additionally, you may evaluate how the addition of Dr Reddys to your portfolios can decrease your overall portfolio volatility.
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
ETFs
Find actively traded Exchange Traded Funds (ETF) from around the world
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
ETF Categories
List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
CEOs Directory
Screen CEOs from public companies around the world
Is Dr Reddys' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Dr Reddys. If investors know RDY will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Dr Reddys listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
0.103
Dividend Share
40
Earnings Share
3.76
Revenue Per Share
272.4618
Quarterly Revenue Growth
0.066
The market value of Dr Reddys Laboratories is measured differently than its book value, which is the value of RDY that is recorded on the company's balance sheet. Investors also form their own opinion of Dr Reddys' value that differs from its market value or its book value, called intrinsic value, which is Dr Reddys' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Dr Reddys' market value can be influenced by many factors that don't directly affect Dr Reddys' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Dr Reddys' value and its price as these two are different measures arrived at by different means. Investors typically determine if Dr Reddys is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Dr Reddys' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.